Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval

The vaccine was 66.1% effective in preventing moderate to severe disease and appeared safe, the US Food and Drug Administration said on Wednesday

The Associated Press February 25, 2021 08:48:25 IST
Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval

Johnson shows vials of the Janssen COVID-19 vaccine in the United States. Johnson and Johnson’s single-dose vaccine protects against COVID-19, according to an analysis by US regulators Wednesday, 24 February, 2021, that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. AP

Washington: Johnson & Johnson's single-dose vaccine offers strong protection against severe COVID-19 , according to an analysis released Wednesday by US regulators that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic.

The long-anticipated shot could offer the nation a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists confirmed that overall the vaccine is about 66 percent effective at preventing moderate to severe COVID-19 , and about 85 percent effective against the most serious illness. The agency also said J&J's shot is safe.

The analysis is just one step in the FDA's evaluation. On Friday, the agency's independent advisers will debate if the evidence is strong enough to recommend the shot. With that advice, the FDA is expected to make a final decision within days.

The COVID-19 death toll in the US topped 500,000 this week, and the vaccination drive has been slower than hoped, hampered by logistical and weather delays. So far, about 44.5 million Americans have received at least one dose of vaccine made by Pfizer or Moderna, and nearly 20 million of them have received the second dose required for full protection.

Tests showed the Pfizer and Moderna vaccines were 95 percent effective at protection against symptomatic COVID-19 .

Dr Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, is part of the FDA advisory panel that will scrutinize the J&J data on Friday and cautions that none of the vaccines have been directly compared. Still, he was encouraged that one dose of the J&J vaccine appears as good at preventing serious illness as its two-dose competitors.

"This is a vaccine to prevent you from going to the hospital and dying at a level that's certainly comparable" to the Pfizer and Moderna vaccines, he said.

J&J tested its single-dose option in 44,000 adults in the US, Latin America and South Africa. Different mutated versions of the virus are circulating in different countries, and the FDA analysis cautioned that it's not clear how well the vaccine works against each variant. But J&J previously announced that the vaccine worked better in the US — 72% effective against moderate to severe COVID-19 , compared with 66 percent in Latin America and 57 percent in South Africa.

South Africa recently began giving the J&J vaccine to front-line health workers on a test basis after deciding that a vaccine from rival AstraZeneca had not shown strong enough study results against the particularly concerning variant spreading there.

"I was reassured" that despite different variants, the J&J shot still protected against serious illness, said Dr Jesse Goodman of Georgetown University, a former FDA vaccine chief. "That's pretty robust data."

In case the vaccines eventually need to be updated, manufacturers are working on adjustments to their recipes. Moderna announced Wednesday that it is ready to begin testing experimental doses that better match the South African version of the virus.

Across all countries, the analysis of the J&J vaccine showed protection began to emerge about 14 days after vaccination. But by 28 days after vaccination, there were no hospitalisations or deaths in the vaccinated group compared with 16 hospitalisations and seven deaths in study recipients who received a dummy shot.

The FDA said effectiveness and safety were consistent across racial groups, including Black and Latino participants.

All of the world's COVID-19 vaccines have been tested differently, making comparisons nearly impossible. It would not be surprising if one dose turned out to be a little weaker than two doses, and policymakers will decide if that's an acceptable trade-off to get more people vaccinated faster.

J&J has another large study underway to see if a second dose of its vaccine works better, raising the prospect that countries could eventually add a booster if one turned out to be warranted.

Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache. No study participant experienced the severe allergic reaction, called anaphylaxis, that is a rare risk of some other COVID-19 shots, although one experienced a less serious reaction.

The FDA said there were no serious side effects linked to the vaccine so far, although it recommended further monitoring for blood clots. In the study, those were reported in about 15 vaccine recipients and 10 placebo recipients, not enough of a difference to tell if the vaccine played any role.

J&J was on track to become the world's first one-dose option until earlier this month. Mexico announced it would use a one-dose version from China's CanSino, which is made with similar technology as J&J's shot but initially was developed as a two-dose option until beginning a one-dose test in the fall.

The Pfizer and Moderna vaccines now being used in the US and numerous other countries must be kept frozen, while the J&J shot can last three months in a refrigerator, making it easier to handle. AstraZeneca's vaccine — widely used in Europe and Britain — is made similarly and also requires refrigeration but takes two doses.

If the FDA clears the J&J shot for US use, it will not boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week. But J&J told Congress this week that it expected to provide 20 million doses by the end of March and 100 million by summer.

European regulators and the World Health Organisation also are considering J&J's vaccine. Worldwide, the company aims to produce around a billion doses by the end of the year.

Updated Date:

also read

COVID-19 surge: AAP MLA Raghav Chadha calls for 'vaccine universalisation' in letter to Narendra Modi
India

COVID-19 surge: AAP MLA Raghav Chadha calls for 'vaccine universalisation' in letter to Narendra Modi

In his letter, the AAP MLA said that the Centre has exported over 64 million doses to 84 countries, while Indian citizens are 'desperately looking for a vaccination centre that is open'

Three women in UP given anti-rabies injections instead of COVID-19 jabs, claim kin
India

Three women in UP given anti-rabies injections instead of COVID-19 jabs, claim kin

The women were administered the shots at a govt-run centre in Shamli. Amid demands for action against the medical staff, health centre in-charge Bijendra Singh said an inquiry will be conducted

Joe Biden set to announce all US adults will be eligible for COVID-19 vaccination on 19 April
World

Joe Biden set to announce all US adults will be eligible for COVID-19 vaccination on 19 April

The White House said Biden is shifting the deadline for full eligibility up from 2 May to 19 April after rapid progress in all 50 states in the vaccine rollouts